Stock CTLT CATALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Catalent, Inc.

Equities

CTLT

US1488061029

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:01 26/04/2024 BST 		5-day change 1st Jan Change
55.92 USD +0.22% Intraday chart for Catalent, Inc. +0.79% +24.46%
04-12 Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 MT
04-08 Sector Update: Health Care Stocks Decline Late Afternoon MT

Business Summary

Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:

- provision of development services and clinical supply services (55.4%);

- subcontracted manufacturing services (44.6%).

Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).

Number of employees: 17,800

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharma and Consumer Health
53.6 %
- - 2,287 53.6 % -
Biologics
46.4 %
2,549 52.8 % 1,978 46.4 % -22.40%
Inter-Segment Revenue Elimination
0.0 %
-17 -0.4 % -2 0.0 % -88.24%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
64.9 %
3,110 64.4 % 2,768 64.9 % -11.00%
Europe
29.5 %
1,506 31.2 % 1,257 29.5 % -16.53%
Other
8.3 %
327 6.8 % 355 8.3 % +8.56%
Elimination of Revenue Attributable to Multiple Locations
-2.7 %
-115 -2.4 % -117 -2.7 % +1.74%

Managers

Managers TitleAgeSince
Alessandro Maselli CEO
 Chief Executive Officer 52 30/09/10
Matti Masanovich DFI
 Director of Finance/CFO 52 04/07/23
Lim Chin Wei CTO
 Chief Tech/Sci/R&D Officer - 31/12/16
Julien Meissonnier CTO
 Chief Tech/Sci/R&D Officer - 18/11/19
Joseph Ferraro CMP
 Compliance Officer 47 12/02/23
Charles Lickfold CTO
 Chief Tech/Sci/R&D Officer - 30/06/20
Paul Surdez IRC
 Investor Relations Contact - 06/01/20
Ricardo Pravda PRN
 Corporate Officer/Principal 53 31/12/04
Michael Hatzfeld AUD
 Comptroller/Controller/Auditor 51 01-15
Karen Murphy Santiago PRN
 Corporate Officer/Principal 53 18/09/22

Members of the board

Members of the board TitleAgeSince
Rolf Classon BRD
 Director/Board Member 79 31/07/14
John Greisch CHM
 Chairman 68 15/02/18
J. Carroll BRD
 Director/Board Member 74 27/07/15
Jack Stahl BRD
 Director/Board Member 71 29/07/14
Donald Morel BRD
 Director/Board Member 67 31/10/15
Frank D'Amelio BRD
 Director/Board Member 66 28/08/23
Gregory Lucier BRD
 Director/Board Member 60 31/03/15
Michael Barber BRD
 Director/Board Member 64 27/04/21
Alessandro Maselli CEO
 Chief Executive Officer 52 30/09/10
Steven Barg BRD
 Director/Board Member 62 28/08/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 180,974,218 175,722,027 ( 97.10 %) 0 97.10 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
11.17 %
20,186,499 11.17 % 1 140 M $
Capital Research & Management Co. (World Investors)
10.56 %
19,079,994 10.56 % 1 077 M $
Janus Henderson Investors US LLC
7.331 %
13,249,339 7.331 % 748 M $
BlackRock Advisors LLC
6.872 %
12,420,915 6.872 % 701 M $
NOMURA HOLDINGS, INC.
6.356 %
11,487,342 6.356 % 648 M $
T. Rowe Price Investment Management, Inc.
6.202 %
11,209,374 6.202 % 633 M $
T. Rowe Price International Ltd.
4.663 %
8,427,340 4.663 % 476 M $
STATE STREET CORPORATION
4.125 %
7,456,058 4.125 % 421 M $
Veritas Asset Management LLP
3.579 %
6,467,989 3.579 % 365 M $
Cadian Capital Management LP
3.355 %
6,064,384 3.355 % 342 M $

Company contact information

Catalent, Inc.

14 Schoolhouse Road

08873, Somerset

+

http://www.catalent.com
address Catalent, Inc.(CTLT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Catalent, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
55.92 USD
Average target price
63.5 USD
Spread / Average Target
+13.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CATALENT, INC. Stock Catalent, Inc.
+24.46% 10.12B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CTLT Stock
  4. Company Catalent, Inc.